BioSpecifics Technologies Corp. Announces Board Authorization of up to $2.5 Million Stock Repurchase Program






LYNBROOK, N.Y., Aug. 17, 2015/ PRNewswire/– BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that came from and remains to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX ® (collagenase clostridium histolyticum or CCH) in the united state as well as XIAPEX ® in Europe, today revealed that its Board of Supervisors has actually accredited an increase in the repurchase amount in the Firm’s stock bought program, previously authorized by the Board in December 2013, under which BioSpecifics is licensed to redeem as much as $2.5 million of its exceptional ordinary shares. This choice shows BioSpecifics’ favorable expectation for the future, self-confidence it will certainly stay lucrative on a recurring yearly basis and also its continued commitment to boosting worth for its investors.

Pursuant to the repurchase program, BioSpecifics plans to buy stock with a broker in the open market, supplied that the timing, actual number as well as price each share of the common stock to be purchased will go through market problems, relevant legal needs, consisting of Regulation 10b-18 of the Securities Exchange Act of 1934, as amended, and also numerous other aspects. BioSpecifics plans to hold any sort of reacquired stock in treasury. The repurchase program may be put on hold or stopped at any moment by the Board of Supervisors. BioSpecifics has no commitment to repurchase common stock under the repurchase program.

Since June 30, 2015, BioSpecifics had 6,847,945 shares of usual stock impressive.

Concerning BioSpecifics Technologies Corp.
. BioSpecifics Technologies Corp. is a biopharmaceutical business that has actually developed injectable collagenase for twelve medical indicators to this day. Injectable collagenase is approved for advertising and marketing as XIAFLEX®(collagenase clostridium histolyticum or CCH) in the UNITED STATE for the therapy of grown-up Dupuytren’s contracture patients with approximately 2 apparent cables in the same hand as well as for Peyronie’s condition in guys with a palpable plaque and also a curvature defect of 30 degrees or better at the beginning of treatment. XIAFLEX is marketed in the U.S. by BioSpecifics’ companion, Endo International plc (Endo), adhering to the purchase of Auxilium Pharmaceuticals, Inc. by Endo. Endo has the adhering to collaborations outside the united state for XIAFLEX in Dupuytren’s contracture as well as Peyronie’s disease; Swedish Orphan Biovitrum ABDOMINAL has marketing rights for XIAPEX ® (the EU tradename for CCH) in 71 Eurasian and African nations, Actelion Pharmaceuticals Ltd. has marketing rights in Canada, Australia, Mexico and also Brazil, and also Asahi Kasei Pharma Company has advertising rights in Japan. CCH remains in scientific growth for the therapy of several added appealing signs. Endo is managing the scientific advancement of CCH for frozen shoulder syndrome as well as cellulite along with growth in canine lipoma. BioSpecifics is currently managing the clinical property development of CCH for the treatment of human lipoma and preclinical growth for uterine fibroids. For even more information, kindly visit www.biospecifics.com. Forward Looking Declarations This release includes” forward-looking declarations”within the meaning of, and made

according to the safe harbor arrangements of, the Personal Securities Litigation Reform Act of 1995. All statements aside from statements of historical reality, consisting of statements concerning the Firm’s method, future operations, future economic placement, future profits, forecasted costs, prospects, strategies as well as objectives of management, anticipated profits growth, and also the assumptions underlying or relating to such statements, are”forward-looking declarations”. The positive declarations in this Report consist of statements worrying, to name a few points, whether BioSpecifics will accomplish its company objectives and also continue to be profitable on a continuous basis; the prepare for the repurchase of stock and reacquired stock; and the suspension or discontinuation of the repurchase program. Sometimes, these declarations can be recognized by forward-looking words such as “anticipate,””likely,””proceed,” “estimations,” “may,””will,””currently,”and also”possible,”the negative or plural of these words, and various other similar expressions. These forward-looking statements are our predictions based on our existing expectations as well as our estimates about future events. There are a number of crucial aspects that might create our actual cause differ materially from those shown by such forward-looking statements, consisting of the capacity of Endo and its partners to attain their particular goals for CCH in their suitable regions; the unpredictabilities integral in the initiation of future clinical tests; Endo or any one of its companions modifying their corresponding goals and/or designating sources various other than to CCH; the prospective market for CCH in a given indication being smaller compared to prepared for; the capacity of CCH to be utilized in extra indicators and also the commencement, timing and outcome of medical tests of CCH for additional indications; the security of the Business’s intellectual building profile; the timing of governing filings as well as activity; the invoice of any repayments from Endo; as well as other threat elements determined in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, our Yearly Record on Kind 10-K for the year finished December 31, 2014 as well as our Existing Reports on Kind 8-K filed with the Stocks and Exchange Compensation. All positive statements consisted of in this discussion are made as of the date hereof, and we assume no commitment to update these positive statements. RESOURCE BioSpecifics Technologies Corp. ASSOCIATED LINKS http://www.biospecifics.com

Advantages Of Plastic Surgery In Modeling

Males and female alike consistently want to look appealing specifically to the members of the other sex. However, not everybody is born with a perfectly flawless face as well as physical body like those of models you see in magazine covers. Some of the hottest models like model Ana Cheri and model Svetlana Bilyalova have each undergone plastic surgical procedures that helped them to progress their careers.

As you age, your face as well as physical body becomes exposed to harmful elements that can create skin irritations and also scarring. A lot more troubles from growing old could occur for both sexes such as loss of hair and boob drooping for example. The very best way to deal with these blemishes is by undertaking some kind of surgical treatment.

Plastic surgery is a really popular and also expensive technique of enhancing ones self. It is not a surprise then that only those who can manage it opt for plastic surgical procedure. Primarily, these are noticeable people in society, stars, versions, and artists. Cosmetic surgery plays a big role in the modeling industry especially.